Roberts, Glore & Co’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Sell |
11,402
-291
| -2% | -$56.5K | 0.61% | 43 |
|
|
2025
Q4 | $2.03M | Sell |
11,693
-442
| -4% | -$80.5K | 0.54% | 44 |
|
|
2025
Q3 | $2.31M | Sell |
12,135
-122
| -1% | -$21.6K | 0.63% | 39 |
|
|
2025
Q2 | $2.2M | Sell |
12,257
-1,462
| -11% | -$254K | 0.64% | 40 |
|
|
2025
Q1 | $2.32M | Sell |
13,719
-720
| -5% | -$118K | 0.71% | 34 |
|
|
2024
Q4 | $2.18M | Sell |
14,439
-217
| -1% | -$33.8K | 0.65% | 36 |
|
|
2024
Q3 | $2.28M | Sell |
14,656
-100
| -0.7% | -$14.9K | 0.66% | 39 |
|
|
2024
Q2 | $2.02M | Sell |
14,756
-468
| -3% | -$64.1K | 0.61% | 43 |
|
|
2024
Q1 | $2.03M | Sell |
15,224
-295
| -2% | -$38.3K | 0.61% | 46 |
|
|
2023
Q4 | $2.14M | Sell |
15,519
-20
| -0.1% | -$2.63K | 0.67% | 40 |
|
|
2023
Q3 | $1.89M | Hold |
15,539
| – | – | 0.63% | 43 |
|
|
2023
Q2 | $2.18M | Sell |
15,539
-233
| -1% | -$32.1K | 0.7% | 34 |
|
|
2023
Q1 | $2.23M | Sell |
15,772
-155
| -1% | -$22.2K | 0.75% | 32 |
|
|
2022
Q4 | $2.49M | Sell |
15,927
-1,740
| -10% | -$250K | 0.87% | 28 |
|
|
2022
Q3 | $2.17M | Sell |
17,667
-70
| -0.4% | -$9.22K | 0.77% | 35 |
|
|
2022
Q2 | $2.36M | Sell |
17,737
-105
| -0.6% | -$14.3K | 0.79% | 36 |
|
|
2022
Q1 | $2.44M | Sell |
17,842
-21
| -0.1% | -$2.93K | 0.7% | 40 |
|
|
2021
Q4 | $3.09M | Buy |
17,863
+134
| +0.8% | +$20.4K | 0.81% | 31 |
|
|
2021
Q3 | $2.58M | Sell |
17,729
-264
| -1% | -$38.6K | 0.78% | 34 |
|
|
2021
Q2 | $2.38M | Sell |
17,993
-175
| -1% | -$22.9K | 0.71% | 42 |
|
|
2021
Q1 | $2.33M | Sell |
18,168
-238
| -1% | -$29.3K | 0.73% | 38 |
|
|
2020
Q4 | $2.19M | Sell |
18,406
-55
| -0.3% | -$6.71K | 0.72% | 39 |
|
|
2020
Q3 | $2.11M | Buy |
18,461
+330
| +2% | +$39K | 0.75% | 37 |
|
|
2020
Q2 | $2.07M | Sell |
18,131
-1,022
| -5% | -$108K | 0.81% | 35 |
|
|
2020
Q1 | $1.54M | Buy |
19,153
+235
| +1% | +$24.3K | 0.66% | 46 |
|
|
2019
Q4 | $2.02M | Buy |
18,918
+5,960
| +46% | +$622K | 0.77% | 38 |
|
|
2019
Q3 | $1.39M | Sell |
12,958
-65
| -0.5% | -$6.67K | 0.85% | 37 |
|
|
2019
Q2 | $1.33M | Sell |
13,023
-75
| -0.6% | -$7.21K | 0.81% | 37 |
|
|
2019
Q1 | $1.18M | Hold |
13,098
| – | – | 0.74% | 45 |
|
|
2018
Q4 | $1.09M | Sell |
13,098
-850
| -6% | -$79.7K | 0.77% | 42 |
|
|
2018
Q3 | $1.5M | Buy |
13,948
+225
| +2% | +$24.7K | 0.86% | 33 |
|
|
2018
Q2 | $1.51M | Sell |
13,723
-295
| -2% | -$30.7K | 0.92% | 31 |
|
|
2018
Q1 | $1.41M | Sell |
14,018
-105
| -0.7% | -$10.8K | 0.87% | 32 |
|
|
2017
Q4 | $1.39M | Sell |
14,123
-415
| -3% | -$39.3K | 0.85% | 32 |
|
|
2017
Q3 | $1.36M | Buy |
14,538
+160
| +1% | +$17K | 0.88% | 33 |
|
|
2017
Q2 | $1.6M | Sell |
14,378
-2,720
| -16% | -$288K | 1.07% | 27 |
|
|
2017
Q1 | $1.68M | Sell |
17,098
-1,090
| -6% | -$104K | 1.16% | 23 |
|
|
2016
Q4 | $1.67M | Sell |
18,188
-200
| -1% | -$17.2K | 1.17% | 26 |
|
|
2016
Q3 | $1.56M | Sell |
18,388
-160
| -0.9% | -$13.4K | 1.12% | 26 |
|
|
2016
Q2 | $1.51M | Sell |
18,548
-170
| -0.9% | -$12.9K | 1.15% | 28 |
|
|
2016
Q1 | $1.34M | Sell |
18,718
-543
| -3% | -$36.4K | 1.01% | 33 |
|
|
2015
Q4 | $1.37M | Hold |
19,261
| – | – | 1.04% | 29 |
|
|
2015
Q3 | $1.18M | Buy |
19,261
+3,055
| +19% | +$214K | 0.92% | 31 |
|
|
2015
Q2 | $1.18M | Sell |
16,206
-400
| -2% | -$29.5K | 0.82% | 38 |
|
|
2015
Q1 | $1.28M | Sell |
16,606
-91
| -0.5% | -$6.52K | 0.88% | 39 |
|
|
2014
Q4 | $1.12M | Sell |
16,697
-185
| -1% | -$11.7K | 0.75% | 44 |
|
|
2014
Q3 | $1.02M | Sell |
16,882
-234
| -1% | -$14.4K | 0.71% | 45 |
|
|
2014
Q2 | $1M | Buy |
17,116
+320
| +2% | +$18.7K | 0.68% | 45 |
|
|
2014
Q1 | $973K | Buy |
16,796
+1,805
| +12% | +$96.7K | 0.67% | 45 |
|
|
2013
Q4 | $803K | Buy |
14,991
+4,295
| +40% | +$255K | 0.56% | 50 |
|
|
2013
Q3 | $661K | Sell |
10,696
-3,005
| -22% | -$180K | 0.49% | 59 |
|
|
2013
Q2 | $831K | Buy |
+13,701
| New | +$816K | 0.51% | 55 |
|
Other funds holding DGX
VCM
VPM
EIG
Roberts, Glore & Co's DGX Position: Q1 2026 in Review
Roberts, Glore & Co reduced its Quest Diagnostics (DGX) stake by 2.5% in Q1 2026, selling an estimated $56.5K and leaving 11,402 shares worth $2.23M. The position accounts for 0.61% of the portfolio, ranked #43.
Roberts, Glore & Co first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.09M in Q4 2021. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Roberts, Glore & Co held 11,402 shares of Quest Diagnostics worth $2.23M as of Q1 2026.
- Roberts, Glore & Co sold 291 Quest Diagnostics shares in Q1 2026, an estimated $56.5K.
- Quest Diagnostics made up 0.61% of Roberts, Glore & Co's portfolio in Q1 2026, its #43 holding.
- Roberts, Glore & Co first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
- Roberts, Glore & Co's Quest Diagnostics position peaked at $3.09M in Q4 2021.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.